New drug shows promise for dangerous pancreatitis complication

NCT ID NCT03401190

First seen Apr 01, 2026 · Last updated Apr 28, 2026 · Updated 5 times

Summary

This study tested an experimental drug called CM4620-IE in 21 people with severe pancreatitis that caused body-wide inflammation (SIRS). The goal was to see if the drug is safe and helps control the disease. Participants received the drug plus standard care or standard care alone. The study explored different doses to find the best approach for future trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE PANCREATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Ben Taub (Baylor College of Medicine)

    Houston, Texas, 77030, United States

  • Detroit Receiving Hospital (Wayne State)

    Detroit, Michigan, 48201, United States

  • Hennepin County Medical Center

    Minneapolis, Minnesota, 55415, United States

  • Henry Ford Hospital

    Detroit, Michigan, 48202, United States

  • MetroHealth (Case Western)

    Cleveland, Ohio, 44109, United States

  • Regions Hospital

    Saint Paul, Minnesota, 55101, United States

  • Riverside Methodist

    Columbus, Ohio, 43214, United States

  • Sinai-Grace Hospital (Wayne State)

    Detroit, Michigan, 48235, United States

  • Washington University

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.